- Laquinimod - Phase III BRAVO trial concluded. Teva plans an additional clinical study before filing a registration application in the US
- TASQ - enrolment of patients for Phase III trial ongoing
- TASQ - Phase II trial published in Journal of Clinical Oncology
- ANYARA - Phase III trial proceeding according to plan
- 57-57 - a clinical trial in being prepared in systemic sclerosis
- ISI - project is proceeding as planned
- RhuDex® - preparations for continued clinical development ongoing
- Net sales SEK 231.3 M (8.5)
- Operating loss SEK 6.2 M (loss: 149.7)
- Loss after tax SEK 1.3 M (loss: 156,8)
- Loss per share for the period amounted to SEK 0,02 (loss: 2.40)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0) 46-19 11 00
This report is also available at www.activebiotech.com
